Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet...
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia
About this item
Full title
Author / Creator
Publisher
Public Library of Science (PLoS)
Journal title
Language
English
Formats
Publication information
Publisher
Public Library of Science (PLoS)
More information
Scope and Contents
Contents
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that accounts for 15-20% of all cases of leukemia. CML is caused by a translocation between chromosomes 9 and 22 which creates an abnormal fusion gene, BCR::ABL1. The amount of BCR::ABL1 transcript RNA is a marker of disease progression and the effectiveness of tyrosine kina...
Alternative Titles
Full title
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_8f718335a7f54f7a832784608c190d61
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_8f718335a7f54f7a832784608c190d61
Other Identifiers
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0265278
